# THRIVE MYELOPROLIFERATIVE NEOPLASMS (MPNS)

Program Resource Guide



## Thriving With an MPN | Self-Advocacy

- Educate yourself about MPNs.
- Ask your doctor if you have had essential testing.
- Participate in shared decision-making with your healthcare team.
- Communicate regularly with your provider, make use of your patient portal.
- Write down questions before and include a care partner at your appointments.
- Consider a second opinion and/or a consult with an MPN specialist.

consider a second opinion and or a consult with an in it specialist.	
Advice for MPN Symptom Management	Considerations for Choosing MPN Therapy
Communicate any issues you are experiencing to your doctor. Evaluate where/why the side effect is happening. Discuss possible dose interruption, dose reduction, or a treatment holiday.	<ul> <li>Set treatment goals with your provider.</li> <li>Medication type.</li> <li>Pre-existing health issues or comorbidities.</li> <li>How treatment is administered or delivered.</li> <li>Financial impact.</li> </ul>
	Advice for MPN Symptom Management  Communicate any issues you are experiencing to your doctor.  Evaluate where/why the side effect is happening.

## **Glossary Terms**

**Anemia (iron deficiency anemia):** A condition that develops when the body lacks sufficient red blood cells. Symptoms of anemia may include fatigue, weakness, and shortness of breath, among others. **Ropeginterferon alfa-2b (BESREMi)**: FDA-approved treatment for patients with polycythemia vera (PV).

**Genetic Testing (molecular profiling or biomarker testing):** Laboratory testing that identifies certain gene mutations, proteins, chromosomal abnormalities and/or other molecular changes that are unique to an individual's disease. In cancer, it may be used to evaluate treatment or to make a prognosis.

**Interferon Therapy:** A type of therapy that interferes with the ability of viruses to reproduce and also boosts the immune system.

**JAK Inhibitors:** A class of therapy that interferes with the activation of the JAK-STAT pathway. **Momelotinib (Ojjaara):** JAK inhibitor therapy approved by the U.S. Food and Drug Administration (FDA) on Sept 15, 2023 for the treatment of intermediate- or high-risk myelofibrosis, in adults with anemia.

**Phlebotomy**: Removal of blood from the veins in order to lower blood volume and to reduce excess red blood cells.

**Pruritis**: Severe itching of the skin, a common and challenging symptom for patients with PV.

**Watch & Wait (or Active Surveillance)**: The period of time before treatment begins in which a patient is monitored for disease progression and symptoms.

#### **MPN Educational Resources**

- American Cancer Society: cancer.org
- MPN Advocacy & Education International: mpnadvocacy.com
- MPN Research Foundation: mpnrf.org
- The Leukemia & Lymphoma Society (LLS): <u>Ils.org</u>
- MPN Voice: mpnvoice.org.uk



Thrive MPNs is brought to you by the Patient Empowerment

Network. Funding is provided by a sponsorship from AbbVie, Inc. and through generous donations from people like you.

#### www.powerfulpatients.org